Win, Lose Or Yawn: Is Industry’s DTC Policy Working?

Despite a strategic shift by industry curtailing playful ads and promotions in favor of a more serious clinical approach, the omission of risk information in advertising remains a pressing problem, FDA Division of Drug Marketing, Advertising & Communications Director Tom Abrams said

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from Archive

More from Pink Sheet